Combination of a Glucagon-Like Peptide 1 Analog and a Sodium-Glucose Cotransporter 2 Inhibitor Improves Lipid Metabolism Compared to the Monotherapies in Experimental Metabolic Syndrome

Background: Obesity is a risk factor for insulin resistance, dyslipidemia, fatty liver disease, and all disorders associated with metabolic syndrome. Here we evaluated the association of glucagon-like peptide 1 (GLP-1) analog, liraglutide, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, canagliflozin, on improvement syndrome symptoms in high-fat diet (HFD)-induced obesity rat model. Methods: Male Wistar rats received either control or HFD ad libitum 5 months. After 4 months diet, were randomly divided into four experimental groups (HFD, + liraglutide canagliflozin). Treatment (100 µg/kg) and/or canagliflozin (10 mg/kg) once daily one month. Body mass food intake monitored throughout experiment. An oral glucose tolerance test, biochemical parameters, epididymal fat, adipocyte morphology assessed after treatment period. Results: Rats developed obesity, intolerance, liver. Liraglutide reduced body weight, normalized lipid profile, abdominal fat. Canagliflozin slightly improved dyslipidemia. The combination therapy was more effective than monotherapies normalizing profile. Conclusions: improving dyslipidemia These results indicate that GLP-1 receptor agonists SGLT-2 inhibitors promising therapeutic strategy to treat possibly prevent disease obese patients. J Endocrinol Metab. 2022;12(6):168-177 doi: https://doi.org/10.14740/jem843